Lexicon Pharmaceuticals Inc (LXRX)
1.74
+0.04
(+2.35%)
USD |
NASDAQ |
May 03, 16:00
1.76
+0.02
(+1.15%)
After-Hours: 20:00
Lexicon Pharmaceuticals Research and Development Expense (Annual): 58.89M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 58.89M |
| December 31, 2022 | 52.82M |
| December 31, 2021 | 55.05M |
| December 31, 2020 | 153.62M |
| December 31, 2019 | 91.92M |
| December 31, 2018 | 100.24M |
| December 31, 2017 | 152.22M |
| December 31, 2016 | 163.97M |
| December 31, 2015 | 95.19M |
| December 31, 2014 | 89.28M |
| December 31, 2013 | 89.68M |
| December 31, 2012 | 82.57M |
| December 31, 2011 | 91.83M |
| Date | Value |
|---|---|
| December 31, 2010 | 78.52M |
| December 31, 2009 | 78.22M |
| December 31, 2008 | 107.23M |
| December 31, 2007 | 104.33M |
| December 31, 2006 | 106.70M |
| December 31, 2005 | 93.62M |
| December 31, 2004 | 90.59M |
| December 31, 2003 | 82.20M |
| December 31, 2002 | 74.86M |
| December 31, 2001 | 53.36M |
| December 31, 2000 | 31.65M |
| December 31, 1999 | 14.60M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
52.82M
Minimum
2022
153.62M
Maximum
2020
82.46M
Average
58.89M
Median
2023
Research and Development Expense (Annual) Benchmarks
| Windtree Therapeutics Inc | 8.341M |
| AIM ImmunoTech Inc | 10.94M |
| Perspective Therapeutics Inc | 21.31M |
| Protalix BioTherapeutics Inc | 17.09M |
| Armata Pharmaceuticals Inc | 33.77M |